Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about MGNX, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Tebotelimab | Gastric Cancer | Phase 2/3 · NCT04082364 | Completed |
| Teplizumab Curtailed Herold Regimen | Type 1 Diabetes Mellitus | Phase 3 · NCT00920582 | Terminated |
| Vobramitamab Duocarmazine (MGC018) | Castration-Resistant Prostatic Cancer | Phase 2 · NCT05551117 | Terminated |
| MGAWN1 | West Nile Neuroinvasive Disease | Phase 2 · NCT00927953 | Terminated |
| Anti-gpA33/CD3 Monoclonal Antibody MGD007 | Colorectal Cancer Metastatic | Phase 1/2 · NCT03531632 | Completed |
| Monoclonal Antibody RAV12 | Pancreatic Cancer | Phase 2 · NCT00625586 | Terminated |
| Flotetuzumab | AML | Phase 1/2 · NCT02152956 | Terminated |
| Flotetuzumab 300 ng/kg/day, continuous… | AML | Phase 1/2 · NCT02152956 | Terminated |
| Izeltabart Tapatansine (IMGC936) | Advanced Solid Tumor | Phase 1/2 · NCT04622774 | Completed |
| Lorigerlimab | Platinum-resistant Ovarian Cancer | Phase 2 · NCT06730347 | Recruiting |
| Vobramitamab Tavatecan (MGC026) | Advanced Solid Tumor | Phase 1 · NCT06242470 | Recruiting |
| Obrindatamab (MGD009) | Mesothelioma | Phase 1 · NCT02628535 | Terminated |
| Enoblituzumab (MGA271) | Melanoma | Phase 1 · NCT02475213 | Completed |
| Hepatitis A Vaccine | Healthy Subjects | Phase 1 · NCT02376036 | Completed |
| Anti-ADAM9/Exatecan Antibody-drug Conjugate… | Advanced Solid Tumors | Phase 1 · NCT06723236 | Recruiting |
| MGC030 | Urothelial Cancer | Phase 1 · NCT07822399 | Recruiting |
Also used in these trials (approved or third-party drugs, not MGNX's own candidates): Retifanlimab, Margetuximab, Trastuzumab, Teplizumab, Capecitabine, Tucatinib, Paclitaxel, Pembrolizumab, Pertuzumab, Prednisone, Regorafenib, Ruxolitinib.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
MGNX had $173.3M in cash and short-term investments on its Jun 30, 2026 balance sheet. Including the cash events since then, it holds about $327M pro forma, before operating spending after that date:
It burns about $38.3M/quarter from operations, an estimated runway of 25.6 months from Jun 30, 2026 at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 18 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when MGNX files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Armistice Capital, LLC | Institution (13G, 5%+) | 6,000,000 | 9.39% | 2026-09-30 |
| BlackRock, Inc. | Institution (13G, 5%+) | 4,503,913 | 7.05% | 2026-06-30 |
| Scott Koenig Director · +41,582 options |
Insider | 867,240 | 1.36% | 2026-02-15 |
| James Karrels SVP and CFO · +175,000 options |
Insider | 206,037 | 0.32% | 2026-02-12 |
| Ezio Bonvini Sr VP, Research & CSO · +298,750 options |
Insider | 193,799 | 0.30% | 2026-10-06 |
| William K Heiden Director · +47,750 options |
Insider | 114,750 | 0.18% | 2026-05-18 |
| Eric Blasius Risser President and CEO, Director · +1.25M options |
Insider | 77,169 | 0.12% | 2026-02-12 |
| Edward Hurwitz Director · +47,750 options |
Insider | 47,824 | 0.07% | 2026-05-18 |
| Thomas Spitznagel Sr VP, Technical Ops · +205,000 options |
Insider | 38,543 | 0.06% | 2026-02-12 |
| Jay Philip Siegel Director |
Insider | 14,750 | 0.02% | 2026-05-18 |
| Federica F. O'Brien Director · +112,711 options |
Insider | 14,750 | 0.02% | 2026-05-18 |
| David C Stump Director · +47,750 options |
Insider | 14,750 | 0.02% | 2026-05-18 |
Share count 63,908,946 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MGNX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →